Emcure Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall

Healthcare · Concall AI · Call held 4 Feb 2026

Company page: Emcure Pharmaceuticals share price, financials & guidance record

Emcure delivered a strong Q3 FY26 performance characterized by robust double-digit growth across all geographies and significant margin expansion. The company is successfully transitioning from branded generics to specialty and innovative products, highlighted by its exclusive partnership with Novo Nordisk for semaglutide. Management outlined a clear 5-year strategic roadmap focused on outperforming industry growth, improving EBITDA margins by 300-400 bps, and achieving a net-debt-free status by late 2028.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q3 FY26: revenue up 20.4%, net profit up 48.1% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
Revenue	2,002	1,963	2,116	2,101	2,270 +13%	2,363 +20%
Expenses	1,621	1,608	1,714	1,684	1,794	1,871
EBITDA	381	355	402	417	475 +25%	493 +39%
Margin	19%	18%	19%	20%	21%	21%
Other income	36	4	-6	0	3	-36
Interest	46	32	39	27	33	38
Depreciation	97	97	97	99	105	105
Profit before tax	273	230	261	291	341 +25%	314 +37%
Tax rate	26%	32%	24%	26%	26%	26%
Net profit	202	156	197	215	251 +24%	231 +48%
EPS	10.29	8.11	9.97	10.92	12.84	12.16

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls